A forum for researchers, students and applicants in the field of cyclodextrin technology
If approved, ZULRESSO would be the first medicine specifically indicated for the treatment of postpartum depression (PPD) Sage Therapeutics (NASDAQ:
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, announced positive
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, delivered eight
Amgen (NASDAQ:AMGN) recently announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA)
There is a not extremely recent but certainly very interesting patent application related to a special use of cyclodextrins, namely
Development of generic formulations with cyclodextrins for oral delivery has been neglected for several decades, since the CD-enabled formulations often
Amgen announced on the 27th August, 2018 the submission of a supplemental New Drug Application (sNDA) to the U.S. Food
Recently, a new patent application became accessible to the public, WO2018146698 (A1), filed by Biophore India, a DMF holder for the
The biggest pharma exhibition in the world, CPHI Worldwide will be organized 9-11th October in Madrid. By joining (which is
